Prema Robinson

Dr. Prema Robinson


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2026 in npj Precision Oncology
Verified
Journal Article
Open access
AMAnirban Maitra
Anirban Maitra
MMMiguel Muñoz
Miguel Muñoz
RCRafael Coveñas
Rafael Coveñas
THTan Hoang
Tan Hoang
ZIZal Sorab Italia
Zal Sorab Italia
PRPrema Robinson
Prema Robinson
The Substance P/neurokinin-1 receptor (SP/NK1R) pathway plays a significant role in several cancers, including pancreatic, breast, glioblastoma, and lung malignancies. This review highlights its involvement in metastasis, angiogenesis, proliferation, resistance, and apoptosis. Aprepitant, an NK1R antagonist and approved antiemetic, shows promising anticancer and protective effects, supporting its use in combination therapies. NK1R-targeted strategies may enhance treatment efficacy while reducing chemotherapy- and radiotherapy-induced toxicities.